Impact of COVID-19 Outbreak on Australian Brain Cancer Market to Witness a Pronounce Growth During Forecast 2023-2028

Report Overview

The Australian Brain Cancer market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Brain cancers include primary brain tumors, which start in the brain and almost never spread to other parts of the body, and secondary tumors (or metastases), which are caused by cancers that began in another part of the body. There are more than 40 major types of brain tumors, which are grouped into two main types they are benign and malignant. A brain tumor may be a primary or secondary cancer. Cancer that first develops in the brain is called primary brain cancer. It rarely spreads to other parts of the body but may spread to other parts of the brain. Sometimes cancer starts in another part of the body and then travels through the bloodstream to the brain. This is known as secondary cancer or metastasis. Every year an estimated 2000 malignant brain tumors are diagnosed in Australia. Malignant spinal cord tumors are rare. About 55 people are diagnosed with malignant spinal cord or other central nervous system tumors each year.

Market Drivers

The market size drivers for the growth of brain cancer diagnostics are expected to propel by technological developments, improvements in diagnostics machines. The rise in the number of cigarette smokers responsible for brain cancer has contributed to the market size.

In 2019, the NDSHS reported current smokers aged 18 and over smoked an average of 12.9 cigarettes per day. Men and women smoked a similar number of cigarettes per day in 2019an average of 13.1 and 12.9 cigarettes per day, respectively.

The population above 60 years of age forms the target demographic segment for this vertical, as this population subset is more prone to neurological conditions. The advancement of diagnostics equipment increases the lifespan of this demographic and improves the quality of life for those suffering from neurological conditions. Hence, the presence of a large geriatric population pool is considered a vital driver for this industry.

Epidemiology

In 2016, there were 1,771 new cases of brain cancer diagnosed in Australia (1,062 males and 709 females). In 2020, it is estimated that 1,879 new cases of brain cancer will be diagnosed in Australia (1,113 males and 767 females).

In 2018, there were 1,410 deaths from brain cancer in Australia (845 males and 565 females). In 2020, it is estimated that there will be 1,518 deaths (921 males and 597 females).

In 20122016, individuals diagnosed with brain cancer had a 22 % chance (21% for males and 24% for females) of surviving for five years compared to their counterparts in the general Australian population.

At the end of 2015, there were 1,317 people living who had been diagnosed with brain cancer that year, 3,279 people living who had been diagnosed with brain cancer in the previous 5 years.

Get Exclusive Free Sample Report @ https://www.prudentmarkets.com/sample-request/139957/

Major Players

Australia presents rewarding opportunities for the key players operating in the Brain Cancer market, owing to growth in awareness about Brain Cancer treatment and the rise in adoption of Brain Cancer treatment products. Moreover, improvement in healthcare infrastructure, rise in the number of hospitals equipped with advanced medical facilities, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. Key players profiled in this report include Roche Diagnostics, Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson & Johnson, and Takeda Pharmaceutical Company Ltd.

The report delivers the challenges in front of the Australian Brain Cancer Market 2023 that allows a better understanding of the market providing a helpful comprehensive evaluation and clear-cut dynamics associated with this market. The analyst has studied the current market scenario while concentrating on the new business objectives with the lucrative opportunities that are available. This report includes changes in customer requirements, customer preferences, and the vendor landscape in the industry with key factors that are expected to influence the overall dynamics of the Australian Brain Cancers Market including the current trends, growth opportunities, restraints, and market drivers.

To Know More About COVID-19 Impact On Australian Brain Cancer Market @ https://www.prudentmarkets.com/sample-request/139957/

Market Segmentation

By Therapy Type:

Based on therapy type, the brain cancer market has been segmented into radiation therapy, chemotherapy, targeted therapy, surgery, and immunotherapy. As of 2015, surgery is anticipated to contribute the highest revenue to the brain tumor and therapeutics market. The low awareness levels and limited treatment options leading to aggravation of the disease to grade IV stage are expected to boost the demand for surgeries.

Radiation therapy is anticipated to exhibit significant growth over the forecast period as this therapy kills the cancer cells by using X-rays, gamma rays, or protons and is the second-best choice after surgery.

By Distribution:

Based on the distribution channel, the market is divided into hospitals, pharmacies, & retail pharmacies, and online pharmacies. Currently, the hospital pharmacies segment accounted for the majority of the Brain Cancer treatment market share, owing to the strong presence of hospital pharmacies, increase in the number of hospitalized Brain Cancer patients, and convenience offered by hospital pharmacies. Online pharmacies are the fastest-growing segment during the forecast period, owing to a rise in awareness regarding online pharmacies, an increase in the number of internet users, and a surge in preference for online purchasing of drugs over the traditional methods.

Major Players

Australia presents rewarding opportunities for the key players operating in the Brain Cancer market, owing to growth in awareness about Brain Cancer treatment and the rise in adoption of Brain Cancer treatment products. Moreover, improvement in healthcare infrastructure, rise in the number of hospitals equipped with advanced medical facilities, developing R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare further contribute to the market growth. Key players profiled in this report include Roche Diagnostics, Astellas Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Ferring Pharmaceuticals Inc., GlaxoSmithKline Plc, Ipsen Pharma, Johnson & Johnson, and Takeda Pharmaceutical Company Ltd.

The Australian Brain Cancer Market report is an easy-to-understand document giving section-wise details about the global market. Starting with the brief outline of the overall market, it will put forth the all-inclusive evaluated market statistics and different parameters for the forecast period. The report covers numerous aspects of the Australian Brain Cancer market divided into product kind, application, and end-use, offering the report to assist the customers in improving their ability to make precise decisions related to the business under the Australian Brain Cancer Market.

International Market Players will use the correct market facts and figures and applied math studies provided within the report back to perceive this and future growth of the worldwide Electrophoretic Australian Brain Cancer market. Each section of the research study is specially prepared to explore key aspects of the global Australian Brain Cancer Market. Buyers of the report will have access to accurate PESTLE, SWOT, and other types of analysis on the global Australian Brain Cancer market. Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries.

This post-pandemic business planning research will aid clients to:
• Adjust their strategic planning to move ahead once business stability kicks in.
• Build resilience by making effective resource and investment choices for individual business units, products, and service lines.
• Conceptualize scenario-based planning to mitigate future crisis situations.

Instant Buy This Report and Get Up To 40% Discount [Use Corporate Email ID]: https://www.prudentmarkets.com/discount-request/139957/

Get full copy of 225+ pages research report (Inclusion of updated research on COVID-19) on United States Region at $1500 and, Europe region at $2000. Get in touch with our sales team, who will guarantee you a report that suits your needs.

Our qualified team of researchers, analysts, and consultants use in-depth qualitative research, quantitative research, and the latest recognized research techniques to offer an unrivaled level of detail and value to your research activities. Our market and competitive intelligence can be utilized by teams across multiple departments, including sales and business development, marketing, to:

• Access the latest information on potential competitors and customers through a comprehensive database
• Analyse the business strategies and collaborations of multiple companies within a specific market
• Identify new markets and regions for future expansion
• Compare financial trends between competitor companies
• Get to know about mergers and acquisitions
• Explore the strengths and weaknesses of companies cross-industry
• Improve your business modeling

Strategic Points Covered in Table of Content of Global Australian Brain Cancer Market:

Chapter 1: Introduction, market driving force product Objective of Study and Research Scope the Australian Brain Cancer market
Chapter 2: Exclusive Summary - the basic information of the Australian Brain Cancer Market.
Chapter 3: Displaying the Market Dynamics- Drivers, Trends and Challenges & Opportunities of the Australian Brain Cancer
Chapter 4: Presenting the Australian Brain Cancer Market Factor Analysis, Porters Five Forces, Supply/Value Chain, PESTEL analysis, Market Entropy, Patent/Trademark Analysis.
Chapter 5: Displaying the by Type, End User and Region/Country
Chapter 6: Evaluating the leading manufacturers of the Australian Brain Cancer market which consists of its Competitive Landscape, Peer Group Analysis, BCG Matrix & Company Profile
Chapter 7: To evaluate the market by segments, by countries and by Manufacturers/Company with revenue share and sales by key countries in these various regions
Chapter 8 & 9: Displaying the Appendix, Methodology and Data Source

(If you have any special requirements, please let us know and we will offer you the report as you want.)

Inquire Before Purchasing The Complete Report To Grow Your Business: https://www.prudentmarkets.com/enquiry-request/139957/

Contact Us:
Allan Carter
Andheri, Maharashtra, 400102
USA/Canada(Toll Free): 1800-601-6071
Direct Line: +91 83560 50278
Mail: sales@prudentmarkets.com
Web: www.prudentmarkets.com

About Us:
We are leaders in market analytics, business research, and consulting services for Fortune 500 companies, start-ups, financial & government institutions. Since we understand the criticality of data and insights, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available. To be at our client's disposal whenever they need help on market research and consulting services. We also aim to be their business partners when it comes to making critical business decisions around new market entry, M&A, competitive Intelligence and strategy.

This release was published on openPR.